Biomarkers of Human Exposure to Pesticides

Introduction: Biomonitoring for pesticide exposure, C.H. Nauman et al. Part 1 Modeling cytochrome P-450 mediated acute nitrile toxicity using theoretical linear solvation energy relationships, George R. Famini et al; changes in biochemical and molecular biological parameters induced by exposure to dioxin-type chemicals, Alan Blankenship and Fumio Matsumura; regulation of muscarine receptors as biomarkers of exposure to insecticides, Amira T. Eldefrawi et al; correlations of molecular connectivity indices with toxicities of organic nitriles, Gordon C. Cash; computer-aided molecular modeling for development of biomarkers for human exposure to pesticides, Mahmoud A. Saleh et al. Part 2 Biomarker measurement methods: a biosensor for monitoring blood cholinesterases as a biomarker of exposure to organophosphorus anticholinesterase pesticides, Mohyee E. Eldefrawi et al; hair as a target tissue for developing a biological marker for precursors to 2,5-hexanedione, Deadre J. Johnson et al; haemoglobin adducts of pesticides, Frank C. Schnell; immunoassay for p-nitrophenol in urine, Kim R. Rogers and J.M. Van Emon; isolation of pesticide-binding protein from rat blood, G.L. Larsen et al; body burden and non-occupational exposure assessment, John A. Santolucito; chronic organophosphorus exposure - biomarkers in the detection of immune dysfunction and the development of lymphomas, David S. Newcombe et al. Part 3 Data analysis and application to risk assessment: validation of a pharmacokinetic model to predict exposure of ground boom mixer-loader-applicators to chlorophenoxyacetic acid herbicides - comparison to conventional approaches, D.G. Baugher; dermal absorption and disposition of formulations of malathion in Sprague-Dawley rats and humans, Curtis C. Dary et al; physiologically-based pharmacokinetic models - examples of their use in exposure and risk assessment, Jerry N. Blancato and Mahmoud A. Saleh; prediction of anticholinesterase activity and urinary metabolites of isofenphos - use of a percutaneous physiologically-based pharmacokinetic-physiologically-based pharmacodynamic model, J.B. Knaak et al; analytic solution of a linear physiologically-based pharmacokinetic model prototype useful in risk assessment, Robert N. Brown.